| PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity SR Gordon, RL Maute, BW Dulken, G Hutter, BM George, MN McCracken, ... Nature 545 (7655), 495-499, 2017 | 1796 | 2017 |
| tRNA-derived microRNA modulates proliferation and the DNA damage response and is down-regulated in B cell lymphoma RL Maute, C Schneider, P Sumazin, A Holmes, A Califano, K Basso, ... Proceedings of the National Academy of Sciences 110 (4), 1404-1409, 2013 | 571 | 2013 |
| Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy AA Barkal, K Weiskopf, KS Kao, SR Gordon, B Rosental, YY Yiu, ... Nature immunology 19 (1), 76-84, 2018 | 431 | 2018 |
| CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer K Weiskopf, NS Jahchan, PJ Schnorr, S Cristea, AM Ring, RL Maute, ... The Journal of clinical investigation 126 (7), 2610-2620, 2016 | 396 | 2016 |
| Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging RL Maute, SR Gordon, AT Mayer, MN McCracken, A Natarajan, NG Ring, ... Proceedings of the National Academy of Sciences 112 (47), E6506-E6514, 2015 | 378 | 2015 |
| Identification of the human mature B cell miRNome K Basso, P Sumazin, P Morozov, C Schneider, RL Maute, Y Kitagawa, ... Immunity 30 (5), 744-752, 2009 | 169 | 2009 |
| Practical immuno-PET radiotracer design considerations for human immune checkpoint imaging AT Mayer, A Natarajan, SR Gordon, RL Maute, MN McCracken, AM Ring, ... Journal of Nuclear Medicine 58 (4), 538-546, 2017 | 119 | 2017 |
| MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas C Schneider, M Setty, AB Holmes, RL Maute, CS Leslie, L Mussolin, ... Proceedings of the National Academy of Sciences 111 (22), 8185-8190, 2014 | 99 | 2014 |
| Structure and dynamics of PD-L1 and an ultra-high-affinity PD-1 receptor mutant R Pascolutti, X Sun, J Kao, RL Maute, AM Ring, GR Bowman, AC Kruse Structure 24 (10), 1719-1728, 2016 | 98 | 2016 |
| Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results. DA Sallman, M Al Malki, AS Asch, DJ Lee, S Kambhampati, ... Journal of clinical oncology 38 (15_suppl), 7507-7507, 2020 | 93 | 2020 |
| The first-in-class anti-CD47 antibody magrolimab combined with azacitidine is well-tolerated and effective in AML patients: phase 1b results DA Sallman, AS Asch, S Kambhampati, MM Al Malki, JF Zeidner, ... Blood 136 (Supplement 1), 330, 2020 | 77 | 2020 |
| CD47–SIRPα-targeted therapeutics: status and prospects R Maute, J Xu, IL Weissman Immuno-Oncology and Technology 13, 100070, 2022 | 58* | 2022 |
| High affinity PD-1 agents and methods of use AM Ring, A Kruse, A Manglik, IL Weissman, RL Maute, MN McCracken, ... US Patent 9,546,206, 2017 | 48 | 2017 |
| SIRP polypeptide compositions and methods of use AM Ring, RL Maute, AC Kruse, A Manglik, KS Lin US Patent 9,845,345, 2017 | 45 | 2017 |
| High affinity PD-1 agents and methods of use AM Ring, A Kruse, A Manglik, IL Weissman, RL Maute, MN McCracken, ... US Patent 9,562,087, 2017 | 42 | 2017 |
| AML-196: the first-in-class anti-CD47 antibody magrolimab in combination with azacitidine is well tolerated and effective in AML patients: phase 1b results D Sallman, A Asch, S Kambhampati, M Al Malki, J Zeidner, W Donnellan, ... Clinical Lymphoma Myeloma and Leukemia 21, S290, 2021 | 37 | 2021 |
| A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients. GA Fisher, NJ Lakhani, C Eng, JR Hecht, JC Bendell, PA Philip, ... Journal of Clinical Oncology 38 (4_suppl), 114-114, 2020 | 37 | 2020 |
| RNAs with multiple personalities RL Maute, R Dalla‐Favera, K Basso Wiley Interdisciplinary Reviews: RNA 5 (1), 1-13, 2014 | 27 | 2014 |
| A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients. NJ Lakhani, A Patnaik, JB Liao, JW Moroney, DS Miller, GF Fleming, ... Journal of Clinical Oncology 38 (5_suppl), 18-18, 2020 | 21 | 2020 |
| Combined blockade of CD47-Sirpa interaction by 5F9 (magrolimab) and azacitidine/venetoclax therapy facilitates macrophage-mediated anti-leukemia efficacy in AML pre-clinical models Y Jia, Q Zhang, C Weng, CL Ramage, Y Nishida, M Chao, RL Maute, ... Blood 138, 510, 2021 | 15 | 2021 |
Irving WeissmanDirector, Institute of Stem Cell Biology and Regenerative MedicineVerified email at stanford.edu
